Barclays analyst Glen Santangelo lowered the firm's price target on Medline to $45 from $50 and keeps an Overweight rating on the shares. The firm says less upside to Q1 estimates, inflationary pressure weighing on the margin outlook, an two secondaries have brought Medline's valuation "to a more palatable level." The firm believes the stock is "poised for multiple expansion post war" and expects the company to "continue racking up share in the interim."
